What is Small Molecule SELEX? SELEX is an iterative in vitro selection process that sifts through a vast random library of nucleic acid sequences (typically 10^13 - 10^15 different molecules) to find the few that bind tightly and specifically to a target. The Challenge with Small Molecules: Low epitope density: Small molecules offer limited surface area for binding, making it hard to find high-affinity aptamers. Immobilization required: They must be attached to a solid support (beads, chip, column) for partitioning, which can mask potential binding sites or introduce non-specific interactions. Negative Selection is Crucial: To avoid selecting aptamers that bind to the immobilization matrix instead of the target. Standard Service Workflow (What the Provider Does): Project Design & Target Immobilization: Consultation: The provider works with you to understand the target's chemistry, desired affinity, and application (e.g., biosensor, therapeutic inhibitor, diagnostic). Conjugation: They chemically conjugate your small molecule to an appropriate carrier (e.g., beads, magnetic particles, agarose resin, or a surface like a chip). This is a critical, proprietary step for many providers. The SELEX Cycle (Repeated 8-15 rounds): Incubation: The vast oligonucleotide library is incubated with the immobilized target. Partitioning: Unbound sequences are washed away. Sequences bound to the target (and unfortunately, sometimes to the matrix) are retained. Elution: Bound…
“Aptamer fields” can be understood as the interconnected research and application areas where aptamers—short, single-stranded DNA or RNA molecules—are designed and used as highly selective binding agents (often described as “chemical antibodies”) for targets ranging from proteins and small molecules to whole cells. This article explains what defines the aptamer fields, how aptamers are created, where they’re used, and what technical trends are shaping the space. 1) What Are Aptamers (and Why They Matter in Aptamer Fields)? Aptamers are typically ~20–100 nucleotides long and fold into 3D structures that bind specific targets with high affinity and specificity. Unlike antibodies (biological proteins), aptamers are nucleic acids, which affects how they are discovered, synthesized, modified, and integrated into devices. Key reasons aptamers have become a “field” rather than a niche tool: Programmability: sequence-controlled design and chemical modification Manufacturability: scalable synthesis routes compared with biological production Versatility: diagnostics, biosensing, therapeutics, imaging, and research reagents 2) The Core Engine: SELEX and How Aptamers Are Discovered Most aptamers are generated using SELEX (Systematic Evolution of Ligands by EXponential enrichment), an iterative in-vitro selection process that enriches sequences that bind a chosen target. In common workflows, a large random library is…
Aptamers are short, single-stranded DNA or RNA sequences that fold into 3D shapes capable of binding specific targets—proteins, small molecules, ions, cells, or even complex mixtures—with high affinity and selectivity. Because they are chemically synthesized, readily modified, and often less immunogenic than protein binders, aptamers have matured into a versatile “molecular toolkit” used across diagnostics, biosensing, therapeutics, imaging, and bioprocessing. This article explains APTAMER APPLICATIONS from fundamentals to advanced use-cases, with an emphasis on how teams translate an aptamer sequence into a functioning assay, sensor, drug carrier, or imaging probe. 1) How Aptamers Are Created (Why Selection Method Shapes Applications) Most aptamers are discovered through SELEX (Systematic Evolution of Ligands by EXponential enrichment): iterative rounds of binding, separation, and amplification that enrich sequences best suited to a chosen target and conditions. Modern SELEX variants—such as cell-SELEX, microfluidic SELEX, and capillary electrophoresis SELEX—aim to shorten selection time, improve specificity, and better match real-world sample environments. The practical result is that application performance often depends as much on selection constraints (buffer, temperature, counter-selection targets, matrix effects) as on the final nucleotide sequence. Key takeaway: If the intended application involves serum, saliva, food extracts, or environmental water, designing SELEX conditions to…
Peptide-Drug Conjugates (PDCs) are targeted therapeutics that chemically link a biologically active drug (“payload”) to a peptide that guides the payload toward a specific receptor, microenvironment, or cellular compartment. Conceptually, PDCs resemble Antibody–Drug Conjugates (ADCs), but replace the antibody with a peptide, aiming to keep targeting precision while improving tissue penetration, manufacturing accessibility, and design flexibility. 1) What Exactly Is a PDC (and Why It Matters)? A typical PDC is built from three modular parts: Targeting peptide (the “homing” component) Linker (the chemical bridge that controls stability and payload release) Payload (cytotoxic drug, radionuclide, or other potent therapeutic) This modular architecture allows researchers to tune the PDC for: circulation stability, selective tissue uptake, cellular internalization, controlled release, and overall safety profile. Why it matters: modern drug discovery increasingly values precision delivery—getting more active agent to diseased tissue while reducing exposure to healthy tissue. PDCs are one of the main “next-generation” strategies being explored to push this idea further. 2) PDCs vs ADCs: Same Strategy, Different Vehicle Both PDCs and ADCs aim to deliver potent therapeutics using a targeting moiety + a linker + a payload. The difference is the targeting “vehicle”: ADCs: antibody-based targeting (large proteins)…